摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2-[(3R,6R)-3-(3-fluoro-2-pyrimidin-2-ylbenzoyl)-6-methylpiperidin-3-yl]oxy-4-methylsulfanylpyridine-3-carboxylate

中文名称
——
中文别名
——
英文名称
methyl 2-[(3R,6R)-3-(3-fluoro-2-pyrimidin-2-ylbenzoyl)-6-methylpiperidin-3-yl]oxy-4-methylsulfanylpyridine-3-carboxylate
英文别名
——
methyl 2-[(3R,6R)-3-(3-fluoro-2-pyrimidin-2-ylbenzoyl)-6-methylpiperidin-3-yl]oxy-4-methylsulfanylpyridine-3-carboxylate化学式
CAS
——
化学式
C25H25FN4O4S
mdl
——
分子量
496.6
InChiKey
DLIVBMLCGJBIRO-SGANQWHYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    35
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    129
  • 氢给体数:
    1
  • 氢受体数:
    10

文献信息

  • 3-ESTER-4-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS
    申请人:Merck Sharp & Dohme Corp.
    公开号:EP2934516A1
    公开(公告)日:2015-10-28
  • USE OF OX1R ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
    申请人:INSERM (Institut National de la Santé et de la Recherche Médicale)
    公开号:EP3223803A1
    公开(公告)日:2017-10-04
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER
    申请人:INSERM (Institut National de la Santé et de la Recherche Médicale)
    公开号:EP3218007A1
    公开(公告)日:2017-09-20
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES
    申请人:INSERM (Institut National de la Santé et de la Recherche Médicale)
    公开号:EP3454857A1
    公开(公告)日:2019-03-20
  • [EN] 3-ESTER-4-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE 3-ESTER-4-SUBSTITUÉS
    申请人:MERCK SHARP & DOHME
    公开号:WO2014099697A1
    公开(公告)日:2014-06-26
    The present invention is directed to 3-ester-4-substituted compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 3-ester-4-substituted compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
查看更多